Oxford Biomedica plc

UK medicines manufacturing is buoyant after its incredible contribution to the pandemic after strong collaboration between industry, academia and government to develop, manufacture, and scale up COVID-19 vaccines. UK’s manufacturing ecosystem has seen increased private and public sector investments into both manufacturing capability and supply chains since the start of the pandemic particularly in existing clusters such as Stevenage and Darlington as well as the Golden Triangle.

BIA’s Policy and Public Affairs Executive, Herbie Lambden, shares his reflections on the political party conference season.

Progress towards the development of COVID-19 vaccines continues as the Cell and Gene Therapy Catapult has stepped up to increase the UK’s capacity and capability to manufacture successful COVID-19 vaccines.

Ahead of the 19th annual bioProcessUK conference (15-17 November, Edinburgh), we spoke to Simon Simpkins PhD, VP, Head of Operational Strategy at Oxford Biomedica about the company's digital future, where the foundational concept of good data management underpins all aspirations. But how do you build that integrated vision and keep the business running at the same time?

The NHS Test and Trace Programme is launched, Gilead’s remdesivir becomes available under the Early Access to Medicines Scheme and BIA members continue to ramp up UK vaccine manufacturing capacity. Plus, the BIA innovates this week with the popular Women in Biotech series moving to a virtual setting!